| Identification | Back Directory | [Name]
Relatlimab | [CAS]
1673516-98-7 | [Synonyms]
ONO-4482
BMS986016
BMS-986016
Relatlimab
Relatlimab (DHD30403)
Relatlimab (anti-LAG-3/CD223)
Research Grade Relatlimab(DHD30403) |
| Hazard Information | Back Directory | [Uses]
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1]. | [References]
[1] Thudium K, et, al. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunol Res. 2022 Aug 18:CIR-22-0057. DOI:10.1158/2326-6066.CIR-22-0057 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|